0.5745
+0.0165
+(2.96%)
At close: January 30 at 7:30:21 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
-212.0000
9,993.0000
--
--
--
Operating Expense
92,073.0000
74,528.0000
82,950.0000
105,618.0000
94,466.0000
Operating Income
-92,285.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
Net Non Operating Interest Income Expense
2,924.0000
1,372.0000
685.0000
555.0000
559.0000
Other Income Expense
-97,949.0000
-56,600.0000
-243.0000
-521.0000
-54.0000
Pretax Income
-187,310.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
Net Income Common Stockholders
-187,310.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
Diluted NI Available to Com Stockholders
-187,310.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
Basic EPS
-1.42
-1.42
-2.18
-4.12
-4.28
Diluted EPS
-1.42
-1.42
-2.18
-4.12
-4.28
Basic Average Shares
131,052.7550
84,244.4940
37,825.4310
25,598.1810
21,966.3260
Diluted Average Shares
131,052.7550
84,244.4940
37,825.4310
25,598.1810
21,966.3260
Total Operating Income as Reported
-92,285.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
Total Expenses
92,073.0000
74,528.0000
82,950.0000
105,618.0000
94,466.0000
Net Income from Continuing & Discontinued Operation
-187,310.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
Normalized Income
-89,503.0000
-63,190.0000
-82,442.0000
-105,584.0000
-93,961.0000
Interest Income
2,924.0000
1,372.0000
685.0000
--
--
Net Interest Income
2,924.0000
1,372.0000
685.0000
555.0000
559.0000
EBIT
-92,285.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
EBITDA
-91,933.0000
-64,181.0000
-82,507.0000
-105,203.0000
-94,086.0000
Reconciled Depreciation
352.0000
354.0000
443.0000
415.0000
380.0000
Net Income from Continuing Operation Net Minority Interest
-187,310.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
Total Unusual Items Excluding Goodwill
-97,807.0000
-56,573.0000
-66.0000
--
--
Total Unusual Items
-97,807.0000
-56,573.0000
-66.0000
--
--
Normalized EBITDA
5,874.0000
-7,608.0000
-82,441.0000
-105,203.0000
-94,086.0000
12/31/2020 - 4/8/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
3G0.BE Altimmune Inc
6.71
-0.52%
NV4.MU Cellectar Biosciences Inc
0.2420
-3.20%
M55.F MacroGenics, Inc.
2.8940
-5.67%
0M4.DU Mersana Therapeutics Inc
0.5906
+2.64%
NV4.F Cellectar Biosciences, Inc.
0.2000
-9.91%
AT20.F Atara Biotherapeutics, Inc.
7.45
-5.70%
1VT.DU Viking Therapeutics Inc
32.15
-1.20%
8AW0.BE Ocean Biomedical Inc
0.1810
-23.31%
8AW0.F Ocean Biomedical, Inc.
0.2200
-34.91%
BX2.BE BioXcel Therapeutics Inc
0.3111
-3.62%